Apoptosis inducer 56

Apoptosis inducer 56 (compound 1) (5-60 μM; 24 h) selectively induces cytotoxicity in MCF-7 human breast cancer cells with an IC₅₀ of 21.18 μM and does not exhibit notable cytotoxicity in non-malignant MCF-10A breast epithelial cells^[1].
Apoptosis inducer 56 (21.18 μM; 24 h) inhibits proliferation and colony formation, and induces S-phase cell cycle arrest in MCF-7 human breast cancer cells^[1].
Apoptosis inducer 56 (21.18 μM; 24 h) induces 45% apoptosis in MCF-7 human breast cancer cells and does not induce apoptosis in non-malignant MCF-10A breast epithelial cells^[1].
Apoptosis inducer 56 (21.18 μM; 24 h) induces DNA damage-mediated apoptosis, and induces mitochondrial membrane depolarization in 75.8% of MCF-7 human breast cancer cells^[1].
Apoptosis inducer 56 (21.18 μM) activates the DNA damage response (upregulates γ-H2AX, p-ATM, p-Chk2) and suppresses DNA repair (downregulates p-BRCA1) in MCF-7 human breast cancer cells^[1].
Apoptosis inducer 56 (21.18 μM; 24 h) induces mitochondria-dependent apoptosis in MCF-7 human breast cancer cells via upregulation of pro-apoptotic proteins, cytochrome c release, caspase activation, and PARP cleavage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.